Company: IMCR
Filing Date: 2025-03-17
Form Type: 8-K
Source: 0001140361-25-008918
Chunk: 0

Company: Immunocore Holdings plc
Filing Date: 2025-03-17
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01.      Other Events.  

On March 17, 2025, Immunocore Holdings plc (the “ Company”) and U. S. Bank Trust Company, National Association, as trustee, entered
into the first supplemental indenture (the “ First Supplemental Indenture”), supplementing the indenture, dated February 2, 2024 (the “ Indenture”) governing the Company's 2.50% Convertible Senior Notes due 2030 (the “ Notes”), to add to the Indenture
certain provisions relating to the Trust Indenture Act of 1939, as amended. A copy of the First Supplemental Indenture is attached hereto as Exhibit 4.1

On March 17, 2025, the Company filed a prospectus supplement (the “ Prospectus Supplement”) to its effective registration statement
on Form S-3ASR (File No. 333-278120) (the “ Registration Statement”) with the U. S. Securities and Exchange Commission, under the Securities Act of 1933, as amended, with respect to the resale by the selling securityholders named therein of up to
$150,000,000 aggregate principal amount of Notes held by such selling securityholders and the American Depositary Shares (“ ADSs”) issuable upon conversion of the Notes, including the ordinary shares, nominal value £0.002 per share, represented by
such ADSs.

In connection with the filing of the Prospectus Supplement, the Company is filing legal opinions of its counsel, Cooley (UK) LLP and
Cooley LLP, regarding the legality of the securities being registered, which opinions are attached as Exhibit 5.1 and 5.2, respectively, to this Current Report on Form 8-K.